Peer Reviewed
Rheumatology clinic

Risedronate: a new bisphosphonate on the block

Andrew L Taylor
Abstract
A new third generation bisphosphonate, risedronate (Actonel), is now available, joining two existing members of this therapeutic class. This article describes the evidence supporting the use of risedronate in osteoporosis and Paget’s disease.
Key Points
    What do we know about risedronate?

    Risedronate, a third-generation bisphosphonate, has potent antiresorptive activity in bone and is therefore of interest in treating metabolic bone disorders. Its efficacy has been evaluated extensively in osteoporosis (postmenopausal and corticosteroid-induced) and Paget’s disease.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?